Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...

Aurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

The land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva...

Aurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...

Aurobindo Pharma reported a fire at its Penicillin-G facility in Kakinada SEZ, damaging ancillary equipment but sparing core infrastructure...

AuroLife Pharma, a wholly-owned step-down subsidiary of the company, has received a warning letter from the United States Food and Drug Adm...

This follows the earlier letter dated June 4, 2020, issuing an OAI (Official Action Indicated) status for this facility.

As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions durin...

The drug firm, however, did not provide any details of the contents of the warning letter received from the regulator.

"The percentage of shareholding in the joint venture company will be 30 per cent and 70 per cent between Helix and Luoxin," Aurobindo Pharm...

The American health regulator has issued nine observations after inspecting the drug maker's Unit 4 formulation facility near Hyderabad in ...

USFDA has conducted an inspection at the company's unit 4, a formulation manufacturing facility in Hyderabad from February 12 to February 2...

Aurobindo Pharma said two of its facilities have undergone inspection by US health regulator USFDA, which has issued observations for one u...

USFDA has lifted the import alert for non-sterile products manufactured at Unit-VI cephalosporin facility based in Hyderabad.

Aurobindo Pharma which has been served notice to shut down its facilities by Andhra Pradesh Pollution Control Board for allegedly violating...

Drug maker Aurobindo Pharma said its consolidated net profit declined 69.08 per cent to Rs 51.50 crore for the first quarter ended June 30,...